DDInter219 DDInter1628
A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Bleomycin {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Bleomycin {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Bleomycin {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is associated with {v} (Gene) JAK1
JAK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Bleomycin {u} (Compound) treats {v} (Disease) melanoma
melanoma {u} (Disease) downregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Bleomycin {u} (Compound) treats {v} (Disease) skin cancer
skin cancer {u} (Disease) is associated with {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Bleomycin {u} (Compound) treats {v} (Disease) melanoma
melanoma {u} (Disease) downregulates {v} (Gene) CAMK1D
CAMK1D {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Bleomycin {u} (Compound) treats {v} (Disease) testicular cancer
testicular cancer {u} (Disease) is associated with {v} (Gene) SLC2A6
SLC2A6 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Bleomycin {u} (Compound) binds {v} (Gene) BLMH
BLMH {u} (Gene) interacts with {v} (Gene) MAST1
MAST1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Bleomycin {u} (Compound) treats {v} (Disease) melanoma
melanoma {u} (Disease) upregulates {v} (Gene) GABPB1
GABPB1 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Bleomycin {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) downregulates {v} (Gene) and {u} (Diease) associated with {v} (Gene) RET
RET {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Bleomycin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Bleomycin (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Bleomycin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is associated with JAK1 (Gene) and JAK1 (Gene) is bound by Ruxolitinib (Compound)
Bleomycin (Compound) treats melanoma (Disease) and melanoma (Disease) downregulates HMGCR (Gene) and HMGCR (Gene) is upregulated by Ruxolitinib (Compound)
Bleomycin (Compound) treats skin cancer (Disease) and skin cancer (Disease) is associated with PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Bleomycin (Compound) treats melanoma (Disease) and melanoma (Disease) downregulates CAMK1D (Gene) and CAMK1D (Gene) is bound by Ruxolitinib (Compound)
Bleomycin (Compound) treats testicular cancer (Disease) and testicular cancer (Disease) is associated with SLC2A6 (Gene) and SLC2A6 (Gene) is downregulated by Ruxolitinib (Compound)
Bleomycin (Compound) binds BLMH (Gene) and BLMH (Gene) interacts with MAST1 (Gene) and MAST1 (Gene) is bound by Ruxolitinib (Compound)
Bleomycin (Compound) treats melanoma (Disease) and melanoma (Disease) upregulates GABPB1 (Gene) and GABPB1 (Gene) is upregulated by Ruxolitinib (Compound)
Bleomycin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) downregulates RET (Gene) and hematologic cancer (Diease) associated with RET (Gene) and RET (Gene) is bound by Ruxolitinib (Compound)